Cambrian Bio
aging biology, mTORC1 inhibition, AMPK activation
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
aging biology, mTORC1 inhibition, AMPK activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cambrian Bio aging biology, mTORC1 inhibition, AMPK activation
Cambrian Bio is a clinical-stage drug development company focused on therapeutics to treat and ultimately prevent debilitating chronic diseases. The company targets biological pathways and mechanisms that decline or malfunction with age. Cambrian operates a distributed company model with multiple pipeline programs and PipeCos developed centrally by its R&D team and collaborators.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cambrian Bio — Translational · Bottom quartile. Derived deterministically from 10 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic